Alar Pharmaceuticals Inc.

Alar Pharmaceuticals Inc. (abbreviated as Alar), a new drug development company, was established in 2016. We focus on developing long-acting release drug products for CNS disorders and chronic diseases, which mainly include opioid use disorder, chronic pain, major depressive disorder, and Parkinson’s disease. A long-acting release product is a solution to improve medical quality, enhance patient compliance, and increase drug adherence. Drug products developed by our platform have distinctive characteristics such as low viscosity, small injection volume, and smooth drug release profile with fewer side effects, which provide a better medical choice for patients. Utilizing the platform, Alar presents a subcutaneous injection, ALA-1000, delivering buprenorphine to treat opioid use disorder (OUD), which is the only 3-month released medication that enters into clinical-stage globally. The proposed buprenorphine systemic exposure resulting from the ALA-1000 injection remains effective over three months per administration and benefits patients by reducing the burden of daily administration, improving patient compliance, and diminishing the concerns of misuse, abuse, and accidental pediatric exposure. We believe that, with the corporate philosophy of improving medical quality, it will reach the milestones of excellence in developing long-acting drug products.